News

Sangamo Therapeutics, Inc. announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen…
Read More...

Gilead Sciences, Inc. announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022). AIDS 2022 will be a hybrid conference, taking place in person in…
Read More...

As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical's new medication DWN12088 has been…
Read More...

February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (“LiberoThera”) to co-develop fully human…
Read More...

Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of transformative precision therapeutics…
Read More...

Valneva SE announces that the European Commission (EC) has approved an amendment to the Advance Purchase Agreement (APA) it signed in November 2021 for Valneva’s inactivated whole-virus…
Read More...

CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, announced the closing of a $100 million Series B round to advance the…
Read More...

AstraZeneca is supplying Switzerland with approximately 1,200 doses of tixagevimab and cilgavimab, a long-acting combination antibody therapy, for the treatment of COVID-19. The Swiss…
Read More...

Karyopharm Therapeutics Inc. announced new regulatory designations for eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) investigational compound being studied for…
Read More...

ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address…
Read More...

Sorrento Therapeutics, Inc. announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic…
Read More...

Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company…
Read More...

Gilead Sciences and the European Commission signed a new joint procurement agreement (JPA) that will ensure continued rapid and equitable access to Veklury (remdesivir) for…
Read More...

Nabriva Therapeutics plc announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the…
Read More...

Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked patients announced the U.S. Food and…
Read More...

AbbVie announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who…
Read More...

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and…
Read More...

Amylyx Pharmaceuticals, Inc. announced a two-year sponsored research agreement with Sunnybrook Research Institute (SRI) to expedite the identification of novel drug candidates that…
Read More...

Moderna, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a…
Read More...

Everest Medicines announced that our partner Calliditas Therapeutics AB has been granted conditional marketing authorization for Kinpeygo (developed under the name NEFECON) by the…
Read More...